Immunomedics, Inc. (NASDAQ:IMMU) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.00.

Several research analysts have weighed in on IMMU shares. Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Immunomedics in a research note on Friday, July 14th. Zacks Investment Research upgraded shares of Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Monday, July 17th. BidaskClub lowered shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Cowen and Company reiterated an “outperform” rating and issued a $15.00 price objective on shares of Immunomedics in a research note on Monday. Finally, ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.

Hedge funds have recently bought and sold shares of the company. Redmile Group LLC acquired a new stake in Immunomedics during the first quarter valued at approximately $21,874,000. State Street Corp increased its stake in Immunomedics by 118.2% in the first quarter. State Street Corp now owns 3,513,549 shares of the biopharmaceutical company’s stock valued at $22,730,000 after buying an additional 1,903,355 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Immunomedics by 1,648.0% in the first quarter. Point72 Asset Management L.P. now owns 1,195,613 shares of the biopharmaceutical company’s stock valued at $7,736,000 after buying an additional 1,127,213 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Immunomedics during the first quarter valued at approximately $3,300,000. Finally, Vanguard Group Inc. increased its stake in Immunomedics by 11.9% in the first quarter. Vanguard Group Inc. now owns 4,416,533 shares of the biopharmaceutical company’s stock valued at $28,574,000 after buying an additional 468,314 shares in the last quarter. 62.02% of the stock is owned by institutional investors.

WARNING: “Immunomedics, Inc. (IMMU) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/25/immunomedics-inc-immu-receives-consensus-recommendation-of-buy-from-brokerages.html.

Immunomedics (NASDAQ IMMU) traded down 1.80% during mid-day trading on Tuesday, reaching $8.75. 944,705 shares of the company’s stock traded hands. The company’s market capitalization is $959.04 million. The company has a 50-day moving average of $8.45 and a 200-day moving average of $6.40. Immunomedics has a 52-week low of $2.02 and a 52-week high of $9.51.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.